DPP-4 inhibitors, neutralizing the DPP-4 enzymatic activity, prevent the peripheral inactivation of incretins (glucose-dependent insulinotropic polypeptide and GLP-1), finally increasing the half-life and promoting the insulinotropism of GLP-1 in T2DM patients. Here, DPP4 is linked to type 2 diabetes mellitus.